<DOC>
	<DOC>NCT01657487</DOC>
	<brief_summary>This study is to investigate and compare treatment efficacy with high and medium dose of fluticasone in combination with salmeterol in COPD patients.</brief_summary>
	<brief_title>Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients</brief_title>
	<detailed_description>Diagnosis and criteria for inclusion and exclusion: Inclusion: 1. Male or female outpatients aged 40 years≧ 2. Current or ex-smoker, with smoking history 10 pack≧- years 3. COPD (FEV1/FVC &lt; 70%) patients with post-bronchodilator FEV1 70% ≦predicted value, without bronchial reversibility (10% increase post ≦bronchodilator) Exclusion: 1. Diagnosis or suspicion of sleep apnea. 2. Concurrent rhinitis, eczema, and asthma. 3. Clinically overt bronchiectasis, lung cancer, active tuberculosis, or other known specific pulmonary disease. 4. A chest X-ray indicating diagnosis other than COPD that might interfere with the study. 5. Major disease abnormalities are uncontrolled on therapy. 6. Alcohol or medication abuse. 7. Patients had lower respiratory tract infections or received systemic steroid in the 4 weeks prior to the commencement of study. 8. Unable or unwilling to comply with all protocol Test product: fluticasone125 mcg/salmetrol 25 mcg ( Seretide 125 Evohaler ) fluticasone250 mcg/salmetrol 25 mcg ( Seretide 250 Evohaler ) Formulation: fluticasone/salmeterol, 125/25 mcg/puff Dose: 2 puffs bid</detailed_description>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>1. Male or female outpatients aged 40 years≧ 2. Current or exsmoker, with smoking history 10 pack≧ years 3. COPD (FEV1/FVC &lt; 70%) patients with postbronchodilator FEV1 70% ≦predicted value, without bronchial reversibility (10% increase post ≦bronchodilator) 1. Diagnosis or suspicion of sleep apnea. 2. Concurrent rhinitis, eczema, and asthma. 3. Clinically overt bronchiectasis, lung cancer, active tuberculosis, or other known specific pulmonary disease. 4. A chest Xray indicating diagnosis other than COPD that might interfere with the study. 5. Major disease abnormalities are uncontrolled on therapy. 6. Alcohol or medication abuse. 7. Patients had lower respiratory tract infections or received systemic steroid in the 4 weeks prior to the commencement of study. 8. Unable or unwilling to comply with all protocol</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>COPD</keyword>
	<keyword>Fluticasone/Salmeterol</keyword>
	<keyword>high dose</keyword>
</DOC>